Aytu Biopharma Inc Stock Price, News & Analysis

Aytu BioPharma (NASDAQ:AYTU) reported strong financial results for Q2 2023, with net revenue reaching $26.3 million, a 14% increase year-over-year. The prescription (Rx) segment alone generated $18.0 million, a growth of 23% compared to the previous year, driven significantly by a 95% surge in pediatric product revenues.

Adjusted EBITDA was positive at $0.7 million, a significant improvement from the $(7.6) million loss reported last year. Despite challenges in the Consumer Health segment, which saw a 3% revenue decline, the company's strategic shift to higher-margin e-commerce sales is expected to bolster profitability.

Aytu BioPharma (Nasdaq:AYTU) is set to report its financial results for the quarter ended December 31, 2022, on February 21, 2023, after market close. The company specializes in pediatric-focused prescription medications and consumer health solutions. A conference call will follow the results at 5:00 pm ET on the same day, accessible via phone or webcast, with a replay available until March 7, 2023. Aytu's portfolio includes ADHD treatments like Adzenys XR-ODT and Cotempla XR-ODT, alongside consumer health products promoting various health needs. For more details, visit aytubio.com.

Aytu BioPharma (NASDAQ:AYTU) announced a delay in filing its Form 10-Q for the second quarter of fiscal year 2023, ending December 31, 2022. The delay is due to an assessment and management review concerning an accounting matter related to warrants issued in previous financings. The Company assures that this issue will not impact assets, cash, revenue, or operational metrics. Aytu plans to file the report as soon as possible and will reschedule its quarterly conference call. The Company focuses on pediatric prescription drugs and consumer health solutions.

Aytu BioPharma (NASDAQ:AYTU) has announced it will report its financial results for the second quarter of fiscal year 2023, ending December 31, 2022, on February 14, 2023, after market close. A conference call will take place the same day at 4:30 pm ET to discuss the results. Interested participants can join by calling (888) 506-0062 or (973) 528-0011 with access code 371594. A live webcast will be available and archived for 90 days. Aytu specializes in pediatric-focused prescription drugs and consumer health solutions, including treatments for ADHD and various vitamin products for children.

Aytu BioPharma, Inc. (NASDAQ:AYTU) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The notification from Nasdaq confirms that Aytu's common stock closed at $1.00 per share or higher for ten consecutive business days, from January 6 to January 20, 2023. The issue is now resolved as per Listing Rule 5550(a)(2). Aytu specializes in pediatric-focused prescription drugs and consumer health products, and its portfolio includes medications for ADHD, allergy relief, and vitamin supplementation for children. This compliance is a positive development for Aytu's market position.

Englewood, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma (NASDAQ:AYTU) announces CEO Josh Disbrow will present at the Lytham Partners Investor Select Conference on January 31, 2023. The event will be held virtually, with a company webcast available at 9:00 am ET on the same day. The presentation can be accessed via the Aytu website. Additionally, management will hold one-on-one meetings with investors throughout the event. Interested parties can arrange meetings through Lytham Partners. Aytu specializes in pediatric-focused prescription drugs and consumer health solutions, including treatments for ADHD and various health products.

Aytu BioPharma is addressing the ongoing supply disruption of generic Adderall by promoting its FDA-approved bioequivalent, Adzenys XR-ODT. This medication is available as an orally disintegrating tablet, providing an alternative for ADHD patients unable to fill their Adderall prescriptions. Aytu's RxConnect program helps patients navigate insurance challenges, offering reduced out-of-pocket costs, often capped at $35 for commercially insured patients. The company emphasizes the importance of maintaining treatment continuity for individuals with ADHD during this time.

Aytu BioPharma (NASDAQ:AYTU) announced a 1-for-20 reverse stock split effective January 6, 2023, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. This decision follows approval from stockholders at a Special Meeting on October 5, 2022. Post-split, approximately 68.8 million shares will be reduced to about 3.4 million. A cash payment will be made for any fractional shares. The compliance deadline is May 22, 2023, requiring a consistent closing bid price of at least $1.00 for ten consecutive business days.

Aytu BioPharma announced a record 5,186 prescriptions for Adzenys XR-ODT for the week ending November 18, 2022, marking a 9.9% increase over the prior 13-week period. This increase is attributed to strong sales force execution and effective use of the Aytu RxConnect patient support program. Adzenys XR-ODT, an FDA-approved bioequivalent to Adderall XR, remains available without disruption, providing an alternative amid ongoing supply issues affecting Adderall. The company ensures consistent production at its Texas facility.